S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
OTCMKTS:CLVLY

Clinuvel Pharmaceuticals (CLVLY) Stock Price, News & Analysis

$9.24
+0.57 (+6.57%)
(As of 03/1/2024 ET)
Today's Range
$8.99
$9.24
50-Day Range
$8.67
$11.10
52-Week Range
$8.61
$13.97
Volume
16,825 shs
Average Volume
4,130 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CLVLY stock logo

About Clinuvel Pharmaceuticals Stock (OTCMKTS:CLVLY)

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

CLVLY Stock Price History

CLVLY Stock News Headlines

Clinuvel Pharmaceuticals Ltd. ADR
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Clinuvel Pharmaceuticals (OTCMKTS:CLVLY) Trading Down 10.7%
Clinuvel Pharmaceuticals Ltd.
Clinuvel Pharmaceuticals Ltd ADR
Clinuvel Pharmaceuticals Ltd ADR CLVLY
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
CLINUVEL Trial Results Show Drug Reduces DNA Damage
CLVLY Clinuvel Pharmaceuticals Limited
CLINUVEL progresses vitiligo treatment program
See More Headlines
Receive CLVLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:CLVLY
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Philippe Jacques Wolgen M.B.A. (Age 61)
    M.D., CEO, MD & Director
    Comp: $1.81M
  • Mr. Darren Michael Keamy B.Com. (Age 51)
    CPA, CFO & Company Secretary
    Comp: $270.98k
  • Dr. Dennis J. Wright
    Chief Scientific Officer
  • Mr. Lachlan Hay
    Director of Global Operations
  • Mr. Malcolm Bull
    Head of Australian Operations & Investor Relations
  • Dr. Rose Quadbeck-Diel
    Senior Vice President of Regulatory Affairs
  • Dr. Azza Hamila
    Head of Quality & Drug Safety














CLVLY Stock Analysis - Frequently Asked Questions

How have CLVLY shares performed in 2024?

Clinuvel Pharmaceuticals' stock was trading at $11.0550 on January 1st, 2024. Since then, CLVLY shares have decreased by 16.4% and is now trading at $9.24.
View the best growth stocks for 2024 here
.

Are investors shorting Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals saw a decline in short interest in the month of February. As of February 15th, there was short interest totaling 100 shares, a decline of 93.3% from the January 31st total of 1,500 shares. Based on an average trading volume of 3,300 shares, the days-to-cover ratio is currently 0.0 days.
View Clinuvel Pharmaceuticals' Short Interest
.

How often does Clinuvel Pharmaceuticals pay dividends? What is the dividend yield for Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals declared a dividend on Wednesday, August 30th. Shareholders of record on Friday, September 8th will be paid a dividend of $0.0283 per share on Monday, October 2nd. The ex-dividend date is Thursday, September 7th. This is a positive change from the stock's previous dividend of $0.02.
Read our dividend analysis for CLVLY
.

How do I buy shares of Clinuvel Pharmaceuticals?

Shares of CLVLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CLVLY) was last updated on 3/3/2024 by MarketBeat.com Staff